CYT-0851 is a small molecule commercialized by Cyteir Therapeutics, with a leading Phase II program in Burkitt Lymphoma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CYT-0851’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for CYT-0851 is expected to reach an annual total of $81 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

CYT-0851 Overview

CYT-0851 is under development for the treatment of relapsed/refractory B-cell non-Hodgkin lymphomas such as diffuse large B-cell lymphoma, mantle cell lymphoma, relapsed/refractory chronic lymphocytic leukemia, relapsed multiple myeloma, triple negative breast cancer, ovarian cancer, recurrent squamous cell carcinoma of the head and neck, soft tissue sarcoma, human epidermal growth factor receptor 2 negative breast cancer (her2- breast cancer), human epidermal growth factor receptor 2 positive breast cancer (her2+ breast cancer), Burkitt lymphoma, small-cell lung cancer, follicular lymphoma and metastatic pancreatic cancer. It is administered orally. The drug candidate acts by targeting RAD51 and is developed based on Cyteir's platform technology.

Cyteir Therapeutics Overview

Cyteir Therapeutics is a biotechnology company. It discovers, develops and commercializes synthetic lethal therapeutics for the treatment of cancer and autoimmune disease. It specializes in the development of small molecules that targets RAD51 to induce synthetic lethality in diseases with a gain-of-function in the gene activation-induced cytidine deaminase (AID). The company focuses on providing treatments for solid tumors, lupus and type 1 diabetes. Cyteir Therapeutics is headquartered in Lexington, Massachusetts, the US.

The operating loss of the company was US$42.3 million in FY2021, compared to an operating loss of US$20.9 million in FY2020. The net loss of the company was US$42.1 million in FY2021, compared to a net loss of US$20.8 million in FY2020.

For a complete picture of CYT-0851’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.